Table 2.
Steady-state pharmacokinetics of isoniazid, rifampin, and pyrazinamide for the nine patients with a full pharmacokinetic curve, as well as for the total cohort
| Parametera | GM (range)b |
||
|---|---|---|---|
| Isoniazid | Rifampin | Pyrazinamide | |
| Total cohort (n = 181) | |||
| C2 h GM in mg/liter (range) | 1.4 (0.2–5.0) | 6.5 (0.1–19.7) | 36.1 (13.5–68.0) |
| C2 h GM in mg/liter (IQR) | 1.4 (0.9–2.2) | 6.5 (5.0–11.7) | 36.1 (32.2–41.4) |
| Proportions with low C2 h levels | 50% (<1.5 mg/liter) | 17% (<4 mg/liter) | 2% (<20 mg/liter) |
| 88% (<3 mg/liter) | 49% (<8 mg/liter) | 39% (<35 mg/liter) | |
| Patients with a full curve (n = 9) | |||
| AUC0–24 in h · mg/liter (range) | 4.4 (1.3–15.0) | 35.4 (26.8–49.9) | 382.4 (270.4–595.9) |
| Cmax in mg/liter (range) | 1.9 (1.0–3.5) | 9.0 (6.6–12.8) | 42.3 (37.3–52.5) |
| Median Tmax in h (range) | 1.0 (1.0) | 3.0 (3.0) | 1.0 (1.0) |
| C2 h GM in mg/liter (range) | 0.9 (0.2–2.7) | 6.6 (3.7–8.8) | 36.2 (30.6–47.0) |
| C2 h GM in mg/liter (IQR) | 0.9 (0.4–2.0) | 6.6 (5.3–8.6) | 36.2 (31.0–39.3) |
| Half-life in h (range) | 1.9 (0.9–4.0) | 1.6 (1.4–1.8) | 6.7 (5.2–9.6) |
a
IQR, interquartile range; Cmax, maximum observed plasma concentration; Tmax, time to Cmax; AUC0–24, area under the plasma concentration-time curve from time zero until 24 h after dose administration; C2 h, plasma concentration 2 h after dose administration.
b
Data are presented as the geometric mean (GM; range, minimum to maximum) except where stated otherwise. C2 h data were missing for isoniazid (n = 2), rifampin (n = 4), and pyrazinamide (n = 2).